Sciensus’ Post

Key Strategies for Successful Orphan Drug Launch in Europe On March 28, I had the pleasure of co-moderating a recent XTalks webinar on the challenges and strategies for launching orphan drugs in Europe. The discussion was insightful and highlighted several key points. Polling Insights: During the webinar, we conducted several polls asking participants about the biggest challenges in launching orphan drugs in Europe. The results were telling: - 44% identified pricing and reimbursement as one of the biggest hurdles. - Another 44% pointed to market access complexities. - 11% mentioned regulatory hurdles. - 36% said tailored market access plans are critical for a successful launch. Expert Quotes: Kirstie Hoyle, CEO of Metabolic Support UK, emphasized the importance of patient association groups: "Patient organisations have access to communities, understand their conditions, and can share information that others can't. This proactive engagement is crucial for successful drug launches.” Andrew Cummins, Vice President and Business Development Lead at Sciensus, highlighted the need for strategic partnerships: "Think about your ambition and all the activities you need to do. Combining efforts under one partner rather than multiple (partners) can make the process smoother and more efficient.” The insights shared by our panellists were invaluable, and I look forward to applying these strategies to our work at Sciensus. #OrphanDrugs #Pharma #Healthcare #PatientCentricity #DrugLaunch #MarketAccess #Sciensus #Europe #XTalks